Pipeline — registered trials by phase
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
— · Pregnancy Related, Atopic Dermatitis · Recruiting · est. 2027-08-15
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
— · Advanced Malignancies · Completed · est. 2022-07-08
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment
— · Hepatic Insufficiency, Liver Diseases · Not Yet Recruiting · est. 2027-03-31
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
— · B-cell Malignancies · Completed · est. 2026-02-26
Study of INCB123667 in Subjects With Advanced Solid Tumors
— · Solid Tumors · Active Not Recruiting · est. 2027-07-27
Study of Ruxolitinib Cream in Children With Atopic Dermatitis
— · Atopic Dermatitis · Completed · est. 2023-08-07
A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
— · Renal Insufficiency, Kidney Diseases · Completed · est. 2023-06-30
A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
— · Advanced Solid Tumors, Metastatic Solid Tumors · Completed · est. 2021-12-14
Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects
— · Acute Graft-versus-host Disease · Completed · est. 2019-11-30
A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes
— · Insulin Resistance, Obesity · Completed · est. 2007-03
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
— · Lymphoma · Completed · est. 2020-05-05
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
— · Colorectal Cancer (CRC), Endometrial Cancer, Melanoma · Completed · est. 2019-11-07
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
— · Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma · Completed · est. 2024-08-29
A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants
— · Healthy Participants · Not Yet Recruiting · est. 2026-10-15
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
— · Advanced Malignancies · Completed · est. 2025-10-13
A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
— · Healthy Participants · Completed · est. 2025-09-29
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
— · Solid Tumors and Hematologic Malignancy · Completed · est. 2009-01
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
— · Hepatic Insufficiency, Liver Diseases · Recruiting · est. 2027-04-13
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
— · Lymphoma · Completed · est. 2021-03-30
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
— · Solid Tumors · Completed · est. 2023-11-17
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707
— · Healthy Participants · Completed · est. 2022-01-25
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
— · Healthy Participants · Recruiting · est. 2026-10-19
A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants
— · Healthy Participants · Completed · est. 2024-09-18
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
— · Moderate to Severe Asthma · Active Not Recruiting · est. 2026-11-20
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
— · Myelofibrosis · Completed · est. 2012-07
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
— · Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia · Recruiting · est. 2028-02-01
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
— · Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer · Completed · est. 2021-04-15
The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
— · Atopic Dermatitis · Completed · est. 2022-11-18
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
— · Advanced Malignancies · Completed · est. 2019-09-17
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
— · MPN (Myeloproliferative Neoplasms) · Completed · est. 2018-12-19
A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy
— · Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma · Not Yet Recruiting · est. 2031-02-25
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
— · Immune Thrombocytopenia · Recruiting · est. 2027-09-23
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
— · Lung Cancer · Completed · est. 2018-12-13
Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
— · Hidradenitis Suppurativa · Completed · est. 2023-10-19
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
— · Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer · Completed · est. 2022-11-28
A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
— · Squamous Cell Carcinoma of Anal Canal · Completed · est. 2020-06-08
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
— · Fibrodysplasia Ossificans Progressiva (FOP) · Recruiting · est. 2027-07-30
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
— · B-Cell Malignancies · Completed · est. 2021-04-12
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
— · Cutaneous Squamous Cell Carcinoma · Active Not Recruiting · est. 2026-09-28
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
— · Non-Small Cell Lung Cancer (NSCLC) · Completed · est. 2023-08-16
A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
— · Rheumatoid Arthritis · Completed · est. 2013-07
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
— · Autoimmune Hemolytic Anemia · Completed · est. 2021-08-05
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
— · Chronic Graft-versus-host-disease · Recruiting · est. 2029-01-31
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
— · Psoriasis · Completed · est. 2009-01-31
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
— · Myelofibrosis, Polycythemia Vera, Thrombocytosis · Completed · est. 2007-12
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus
— · Cutaneous Lichen Planus · Completed · est. 2023-10-02
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
— · Hidradenitis Suppurativa, Acne Inversa · Completed · est. 2021-12-15
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
— · NonSegmental Vitiligo · Completed · est. 2022-05-24
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
— · NonSegmental Vitiligo · Active Not Recruiting · est. 2026-03-17
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
— · Atopic Dermatitis · Completed · est. 2025-05-21
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
— · Vitiligo · Completed · est. 2022-11-14
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
— · Hidradenitis Suppurativa (HS) · Recruiting · est. 2028-02-28
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
— · Polycythemia Vera · Completed · est. 2014-01-15
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
— · Non-segmental Vitiligo · Completed · est. 2021-03-15
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
— · Hidradenitis Suppurativa · Active Not Recruiting · est. 2026-10-09
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
— · NonSegmental Vitiligo · Recruiting · est. 2027-04-30
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
— · CRC (Colorectal Cancer) · Recruiting · est. 2028-12-29
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
— · Diffuse Large B-cell Lymphoma · Active Not Recruiting · est. 2026-09-01
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Incyte is lead sponsor; 59 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-08-31Current report (material event)
- 10-Q2026-07-28Quarterly report
- 8-K2026-07-28Current report (material event)
- 8-K2026-07-06Current report (material event)
- 8-K2026-06-22Current report (material event)
- 8-K2026-06-09Current report (material event)
- 8-K2026-06-08Current report (material event)
- DEFA14A2026-05-27DEFA14A
- SCHEDULE 13G/A2026-05-14SCHEDULE 13G/A
- SCHEDULE 13D/A2026-05-11SCHEDULE 13D/A
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- ARS2026-04-28Annual report to holders
- DEFA14A2026-04-28DEFA14A
- DEF 14A2026-04-28Proxy statement
- 10-Q2026-04-28Quarterly report
- 8-K2026-04-28Current report (material event)
- 8-K2026-03-30Current report (material event)
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 8-K2026-03-26Current report (material event)
- 8-K2026-03-06Current report (material event)
- SCHEDULE 13D/A2026-02-10SCHEDULE 13D/A
- 10-K2026-02-10Annual report
- 8-K2026-02-10Current report (material event)
- 8-K2025-12-12Current report (material event)
- SCHEDULE 13G2025-11-10SCHEDULE 13G
- SCHEDULE 13G2025-11-07SCHEDULE 13G
- 10-Q2025-10-28Quarterly report
- 8-K2025-10-28Current report (material event)
- SCHEDULE 13G/A2025-10-17SCHEDULE 13G/A
- 8-K2025-10-03Current report (material event)
- 8-K2025-08-07Current report (material event)
- 10-Q2025-07-29Quarterly report
- 8-K2025-07-29Current report (material event)
- S-82025-07-02Employee stock plan
- 8-K2025-06-27Current report (material event)
- S-82025-06-18Employee stock plan
- S-82025-06-18Employee stock plan
- 8-K2025-06-11Current report (material event)
- 8-K2025-05-14Current report (material event)
- ARS2025-04-29Annual report to holders
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.